Form 4: Maze Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Jason Coloma V, Chief Executive Officer and a Director of Maze Therapeutics, Inc., sold 22,638 shares of common stock on September 2, 2026.
Summary
- Open-market sale: disposed of 9,852 Common Stock at $26.38 ($259,856) on September 2, 2026; holds 40,148 after (Direct).
- Open-market sale: disposed of 1,375 Common Stock at $27.12 ($37,292) on September 2, 2026; holds 38,773 after (Direct).
- Open-market sale: disposed of 11,282 Common Stock at $26.01 ($293,482) on September 3, 2026; holds 27,491 after (Direct).
- Open-market sale: disposed of 129 Common Stock at $25.77 ($3,325) on September 3, 2026; holds 27,362 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $593,955 of stock on the open market.
Insider Transactions
Jason Coloma V — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-02 | Open-market sale | Common Stock | 9,852 | $26 | $259.9K | 40,148 |
| 2026-09-02 | Open-market sale | Common Stock | 1,375 | $27 | $37.3K | 38,773 |
| 2026-09-03 | Open-market sale | Common Stock | 11,282 | $26 | $293.5K | 27,491 |
| 2026-09-03 | Open-market sale | Common Stock | 129 | $26 | $3.3K | 27,362 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-02 | Open-market sale (9,852 shares) |
| 2026-09-02 | Open-market sale (1,375 shares) |
| 2026-09-03 | Open-market sale (11,282 shares) |
| 2026-09-03 | Open-market sale (129 shares) |
Keywords
insider transaction, Form 4, MAZE, Maze Therapeutics, Inc., bearish, Jason Coloma V
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.